Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

Poly(ADP‐Ribose) Polymerase (PARP) Inhibitors for locally advanced or metastatic breast cancer

This is not the most recent version

view the current version 22 April 2021

Information

DOI:
https://doi.org/10.1002/14651858.CD011395Copy DOI
Database:
  1. Cochrane Database of Systematic Reviews
Version published:
  1. 26 November 2014see what's new
Type:
  1. Intervention
Stage:
  1. Protocol
Cochrane Editorial Group:

  1. Cochrane Breast Cancer Group

Copyright:
  1. Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Article metrics

Altmetric:

Cited by:

Cited 0 times via Crossref Cited-by Linking

Collapse

Authors

  • Mustafa Khasraw

    Correspondence to: NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia

    [email protected]

    [email protected]

  • Sujata M Patil

    Epidemiology and Biostatistics, Memorial Sloan‐Kettering Cancer Center, New York, USA

  • Tiffany A Traina

    Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, USA

  • Mark E Robson

    Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, USA

Contributions of authors

  1. Draft the protocol: MK, SMP, MR

  2. Study selection: MK, TT, MR

  3. Extract data from studies: MK, TT, MR

  4. Enter data into RevMan: MK, MR

  5. Carry out the analysis: MK, SMP, MR

  6. Interpret the analysis: MK, SMP, TT, MR

  7. Draft the final review: MK, SMP, TT, MR

  8. Disagreement resolution: MK, SMP, TT, MR

  9. Update the review: MK, SMP, TT, MR

Declarations of interest

Dr Robson has served on advisory boards for Astra‐Zeneca, Pfizer, and Abbott Pharmaceuticals, all of which have PARP inhibitors under development. Dr Robson's institution also received funding from Astra‐Zeneca to conduct a clinical trial of a PARP inhibitor.

Acknowledgements

The authors would like to thank Melina Willson from the Cochrane Breast Cancer Group for her assistance and coordinating this review protocol.

Version history

Published

Title

Stage

Authors

Version

2021 Apr 22

PARP (Poly ADP‐Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer

Review

Amelia M Taylor, David Lok Hang Chan, Martin Tio, Sujata M Patil, Tiffany A Traina, Mark E Robson, Mustafa Khasraw

https://doi.org/10.1002/14651858.CD011395.pub2

2014 Nov 26

Poly(ADP‐Ribose) Polymerase (PARP) Inhibitors for locally advanced or metastatic breast cancer

Protocol

Mustafa Khasraw, Sujata M Patil, Tiffany A Traina, Mark E Robson

https://doi.org/10.1002/14651858.CD011395

PICOs

Population
Intervention
Comparison
Outcome

The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.

See more on using PICO in the Cochrane Handbook.